Not the highest quality company listed on the ASX, but a short-term (18 months) thesis could play out here, I have 60% confidence in this playing out:
- Recent quarters demonstrate an inflection point where cash flow breakeven can now be sustained (although certainly not consistent), indicating improved operational efficiency and financial stability.
- KKR's acquisition of shares in MedAdvisor on the market suggests some validation of Andrew Smith's thesis (Perenial); emphasising that the company's transformation into a profitable business will make it takeover attractive.
- Andrew Smith highlights MedAdvisor's attractive valuation metrics, trading at 1.5x revenue compared to peers in the US at five times sales. My opinion is that a takeover offer could potentially be executed at 3x revenue, indicating good upside potential from the current stock price.